MDXG logo

MIMEDX GROUP INC

MDXGNASDAQ
πŸ† #2750 by market capEarnings Oct 27US Equity
$623.00β–Ό $36.45 (βˆ’5.85%)
Simulated price
πŸ””
Track MDXG
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 5.8%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$681M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-2.4%
Declining
πŸ“ŠGross Margin
78.8%
High
πŸ’΅FCF Margin
19.5%
Healthy
βš–οΈP/S Ratio
1.9x
Cheap
Otter Score
80
Good
No chart data available for MDXG.

Trading Snapshot

Day Range
$617.85 – $627.41
52-Week Range
$3.03 – $7.97
Volume
$3.68B
Avg Volume
$3.45B
Shares Outstanding
145.8M
Next Earnings
Dec 7, 2026

Fundamentals Snapshot

Annual Revenue
$419M
Last Q Revenue
$64M
P/E Ratio
109.1
P/S Ratio
1.9x
EPS (TTM)
$0.04
Dividend Yield
β€”
Dilution (1yr)
+0.5%

Why Investors Own MDXG

  • βœ“High-growth profile β€” revenue up +5.8% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 62% gross margin and 16% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

MDXG logo

MIMEDX GROUP INC

MDXG
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$419Mβ–² +20.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
82.6%β–Ό βˆ’0.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$64Mβ–² +8.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$73Mβ–² +13.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
149.7Mβ–² +0.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$144Mβ–² +$64M YoY
StockOtter Β· stockotter.space

About MIMEDX GROUP INC

MiMedx Group, Inc. specializes in creating and supplying allografts derived from placental tissue, serving a diverse range of medical fields. The company employs its unique, patented PURION process to treat human placental tissues, a method crucial for manufacturing allografts that preserve the natural biological characteristics and essential regulatory proteins of the original tissue. This exclusive and patented processing technique incorporates both aseptic procedures and a final sterilization step, ensuring product safety and efficacy. Among its offerings is EpiFix, a semi-permeable membrane designed to act as a protective barrier, effectively treating persistent wounds such as diabetic foot ulcers, venous leg ulcers, and pressure sores. Another key product is AmnioFix, a protective, semi-permeable allograft made from dehydrated human amnion/chorion membrane, utilized to aid post-surgical recovery. EpiCord and AmnioCord, both derived from dehydrated human umbilical cord, function as allografts that foster a protective healing environment and are applied in both advanced wound care and surgical recovery contexts. AMNIOBURN is also a semi-permeable protective allograft specifically developed for managing partial and full-thickness burn injuries. Its flagship product, mdHACM, is a micronized, powdered version of AMNIOFIX. These products predominantly find use in healthcare sectors like wound management, burn treatment, surgical procedures, and non-operative sports medicine. Additionally, the company supplies allografts for dental uses to other manufacturers on an original equipment manufacturer (OEM) basis. Distribution of its products primarily occurs within the United States, facilitated by its own sales teams, independent agents, and various independent distributors. MiMedx Group, Inc.'s main office is located in Marietta, Georgia.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Good
80/100

Analyst Ratings

β“˜
Consensus
Buy
11 analysts
Strong Buy2
Buy8
Hold1
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates